Pleiotropic beneficial cardiometabolic actions of a high‐purity eicosapentaenoic acid product in high cardiovascular risk individuals
Lipids · 2024
DOI: 10.1002/lipd.12391 ↗Kurz gefasst
Fachartikel in der Zeitschrift Lipids, 2024. Verfasst von Charalampos I Liakos und 3 weiteren Autor:innen. Beteiligte Einrichtung: National and Kapodistrian University of Athens, 1st University Department of Cardiology, Hippokration General Hospital of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Eicosapentaenoic Acid, Cardiovascular Diseases. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Libytec Pharmaceutical S.A..
Abstract (Originalsprache)
The ideal approach to the secondary dyslipidemia goal of lowering triglycerides (TG) is not well established. The available ω‐3 fatty acid products differ from each other in composition and content. The purpose of the present study was to investigate the effect of a highly purified eicosapentaenoic acid (EPA) formulation on cardiometabolic biomarkers in high cardiovascular (CV) risk patients. The study included 226 subjects with high TG and ≥1 of the following CV risk factors: arterial hypertension, diabetes mellitus, ultrasound‐documented atheromatosis, peripheral artery disease, previous myocardial infarction, or ischemic stroke. Participants received 2 g EPA twice daily for 3 months, along with typical nutritional counseling. Cardiometabolic hematological parameters (TG, low‐density lipoprotein [LDL], high‐density lipoprotein [HDL], non‐HDL, total cholesterol [TChol], apolipoprotein A 1 [Apo A 1 ], apolipoprotein B [Apo B], glucose, glycated hemoglobin [HbA 1 c], and C‐reactive protein [CRP]) were measured at baseline and at 3 months. The mean patients' age was 61.1 ± 1.4 years and the mean baseline TG was 2.97 ± 0.15 mmol/L. Apart from Apo A 1 , all other biomarkers significantly ( p < 0.05) improved at 3 months, regardless of sex (except Apo B) and age: TG 1.75 ± 0.09 versus 2.97 ± 0.15 mmol/L, LDL 2.46 ± 0.08 versus 3.05 ± 0.13 mmol/L, HDL 1.22 ± 0.03 versus 1.11 ± 0.03 mmol/L, non‐HDL 3.29 ± 0.10 versus 4.14 ± 0.16 mmol/L, TChol 4.55 ± 0.10 versus 5.15 ± 0.13 mmol/L, Apo A 1 26.8 ± 9.3 versus 22.5 ± 8.6 μmol/L, Apo B 1.25 ± 0.23 versus 1.29 ± 0.23 μmol/L, glucose 5.66 ± 0.11 versus 5.99 ± 0.17 mmol/L, HbA 1 c 5.83 ± 0.1 versus 5.97 ± 0.1% and CRP 1.92 ± 0.2 versus 5.26 ± 2.8 mg/L. In conclusion, adding highly purified EPA product (4 g daily) on nutritional counseling leads to a significant TG reduction. In addition, this treatment appears to have pleiotropic beneficial cardiometabolic actions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National and Kapodistrian University of Athens, 1st University Department of Cardiology, Hippokration General Hospital of Athens, Athens, Greece.
- Private Practice.
- Department of Internal Medicine, General Hospital of Lamia, Lamia, Greece.
- ESH Center of Excellence for Hypertension, Department of Cardiology, Laiko General Hospital of Athens, Athens, Greece.
ORCID-Profile: Charalampos I Liakos
Förderung
- Libytec Pharmaceutical S.A.
Zitieren
APA
Liakos, C. I., Lanaras, L., Bristianou, M., & Papadopoulos, D. P. (2024). Pleiotropic beneficial cardiometabolic actions of a high‐purity eicosapentaenoic acid product in high cardiovascular risk individuals. Lipids. https://doi.org/10.1002/lipd.12391
Vancouver
Liakos CI, Lanaras L, Bristianou M, Papadopoulos DP. Pleiotropic beneficial cardiometabolic actions of a high‐purity eicosapentaenoic acid product in high cardiovascular risk individuals. Lipids. 2024. doi:10.1002/lipd.12391
BibTeX
@article{Liakos2024,
author = {Liakos, Charalampos I and Lanaras, Leonidas and Bristianou, Magdalini and Papadopoulos, Dimitrios P},
title = {Pleiotropic beneficial cardiometabolic actions of a high‐purity eicosapentaenoic acid product in high cardiovascular risk individuals},
journal = {Lipids},
year = {2024},
doi = {10.1002/lipd.12391}
}
EUVIMED